Parkinson Disease

An open-label phase 2b trial assessing ND0612 showed that the rate of treatment responders increased over a 12-month period among patients with Parkinson disease who experienced motor fluctuation.

ND0612, an investigational agent, had supportive data from the pivotal phase 3 BouNDless trial, a large-scale, phase 3 study of patients with Parkinson disease.

Patients with Parkinson disease and depression exhibit significantly worse nonmotor symptoms, highlighting the need for comprehensive management including orthostatic hypotension, constipation, and hyposexuality.

After 28 days of treatment, bezisterim showed pronounced effects on measures of the Non-Motor Symptom Scale, as well as greater achievement of ON time than levodopa alone.

Following presented phase 1 clinical trial findings at AAN 2024, bemdaneprocel receives regenerative medicine advanced therapy designation by the FDA for the treatment of Parkinson disease.

According to recent studies and the latest insights provided by experts, early developments in gene and cell therapies show promise for patients living with Parkinson disease, but challenges remain.

Mike Hooven, chairman and CEO of Enable Injections, and Randall Moreadith, MD, PhD, chief development officer of Serina Therapeutics, provided insight on the development plans of SER-252, an investigational apomorphine therapy for advanced Parkinson disease.

The lead neuroscientist and lead data scientist at Rune Labs talked about leveraging mobility data to monitor progression in patients with Parkinson disease. [WATCH TIME: 7 minutes]

Khashayar Dashtipour, MD, PhD, an associate professor of neurology at the Loma Linda University Health System, provided an overview of an upcoming CME-credited educational course on movement disorders scheduled for June 1st in Minnetonka, Minnesota.

The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]

The professor of neurological surgery at Weill Cornell medicine talked about the regulatory hurdles and challenges in patient selection and delivery methods for gene therapy in Parkinson disease. [WATCH TIME: 5 minutes]

In a recent study assessing basal ganglia activity during REM sleep, results revealed that elevated beta power may be correlated with the severity of REM sleep behavior disorder in Parkinson disease.

Depression prior to PD diagnosis predicts increased dementia risk and mortality, emphasizing its significance in disease progression.

Clinical trials assessing cell therapies for Parkinson disease treatment may show early potential in improving both motor and nonmotor symptoms.

Kremens gave closing thoughts on the promise of the Parkinson disease research field, the outlook of drug development, and what clinicians should be excited for next.

Daniel Kremens, MD, JD, described positive 18-month data on bemdaneprocel, an investigational cell-based approach for patients with Parkinson disease.

The director for the Gene Therapy Institute at The Ohio State University talked about the latest developments in gene therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]

ASPIRO, an open-label trial, will assess the safety and tolerability of ANPD001, an investigational autologous neuronal replacement therapy being studied as a regenerative therapy for PD.

Neurology News Network. for the week ending May 4, 2024. [WATCH TIME: 3 minutes]

The chief scientific officer of the Parkinson’s Foundation and chief executive officer of Tasso discussed their company partnership to expand and accelerate genetic research in Parkinson Disease. [WATCH TIME: 6 minutes]

In this segment, Kremens described pump therapies currently in development, such as ND0612 and ABBV-951.

Kremens gave thoughts on the use of several investigational continuous agents, including IPX203, risvodetinib, and P2B001.

As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.

Neurology News Network. for the week ending April 27, 2024. [WATCH TIME: 3 minutes]

In this conversation, Kremens discussed the common use of antiemetics in Parkinson disease, the real-world data surrounding these agents, and whether there are certain clinical advantages to apomorphine hydrochloride injection.

A recent study showed the relationship between genes associated with lysosomal function and environmental exposure to pesticides in Parkinson disease.

Daniel Kremens, MD, JD, provided commentary on a number of various amantadine formulations for Parkinson disease, and how timing of dosing impacts efficacy.

Kenneth Ngo, MD, medical director for the Brain Injury Program at Brooks Rehabilitation’s 3 inpatient hospitals, highlighted how cotreatment between music therapy and physical therapy can significantly improve the overall quality of life for patients with Parkinson disease.

Using the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score, SAGE-718 failed to distinguish itself from placebo.

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.